Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2016

Primary Completion Date

March 5, 2020

Study Completion Date

March 5, 2020

Conditions

Primary Peritoneal Carcinoma

Interventions

DRUG

Tremelimumab

DRUG

Olaparib

Trial Locations (1)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore